Chemistry:Suritozole

From HandWiki
Short description: Chemical compound
Suritozole
Suritozole.svg
Clinical data
ATC code
  • none
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC10H10FN3S
Molar mass223.27 g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Suritozole (MDL 26,479) is an investigational cognition enhancer. It acts as a partial inverse agonist at the benzodiazepine receptor site on the GABAA ion channel complex, but does not have either anxiogenic or convulsant effects, unlike other BZD inverse agonists such as DMCM.[1] It was investigated for the treatment of depression and Alzheimer's disease,[2] but clinical development seems to have been discontinued.

Synthesis

Synthesis:[3][4] ~85%:[5] Patents:[6][7] etc

The reaction between monomethylhydrazine [60-34-4] (1) and methyl isothiocyanate (Trapex) [556-61-6] (2) gave 2,4-dimethylthiosemicarbazide [6621-75-6] (3). Amide formation with 3-fluorobenzoyl chloride [1711-07-5] (4) yielded 1-(3-fluorobenzoyl)-2,4-dimethylthiosemicarbazide [110623-52-4] (5). Cyclization to Suritozole (6).

See also

References

  1. "MDL 26,479: a potential cognition enhancer with benzodiazepine inverse agonist-like properties". Br. J. Pharmacol. 107 (1): 78–86. September 1992. doi:10.1111/j.1476-5381.1992.tb14466.x. PMID 1330168. 
  2. "Pharmacokinetics of MDL 26479, a novel benzodiazepine inverse agonist, in normal volunteers". Biopharm Drug Dispos 18 (4): 325–34. May 1997. doi:10.1002/(SICI)1099-081X(199705)18:4<325::AID-BDD21>3.0.CO;2-1. PMID 9158880. 
  3. Miller, JA; Dudley, MW; Kehne, JH; Sorensen, SM; Wenstrup, DL; Kane JM;. MDL 26,479 Drugs Fut 1992, 17, 1, 21.
  4. Kane, John M.; Dudley, Mark W.; Sorensen, Stephen M.; Miller, Francis P. (1988). "2,4-Dihydro-3H-1,2,4-triazole-3-thiones as potential antidepressant agents". Journal of Medicinal Chemistry. 31 (6): 1253–1258. doi:10.1021/jm00401a031.
  5. Louks, David H.; Stolz-Dunn, Sandra K. (2007). "Kinetics for Scale-Up of a One-Pot Pathway to 5-(3-Fluorophenyl)-2,4-dihydro-2,4-dimethyl-3H-1,2,4-triazole-3-thione Using a Hybrid Model of Parallel and Consecutive Reactions". Organic Process Research & Development. 11 (5): 877–884. doi:10.1021/op700101g.
  6. US5856350 idem Christopher Robin Dalton, John Michael Kane, John Herr Kehne, WO patent 1996033177 (1999 to Hoechst Marion Roussel, Inc.).
  7. US5723624 idem Sandra K. Stolz-Dunn, David H. Louks, Yolanda M. Puga, Christian T. Goralski, WO patent 1996001812 (1998 to Merrell Pharmaceuticals Inc).

{{Navbox | name = GABA receptor modulators | title = GABA receptor modulators | state = collapsed | bodyclass = hlist | groupstyle = text-align:center;

 | group1 = Ionotropic
 |  list1 = {{Navbox|subgroup
 | groupstyle = text-align:center
 | groupwidth = 5em
   | group1 = GABAA
   | list1  = 
   | group2 = GABAA
   | list2  = 
 }}
 | group2 = Metabotropic

| list2 =

 | below = 
See also
Receptor/signaling modulators
GABAA receptor positive modulators
GABA metabolism/transport modulators

}}